Literature DB >> 18799794

Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.

Henry N Ginsberg, Rajasekhar Ramakrishnan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18799794      PMCID： PMC3275632          DOI： 10.1161/ATVBAHA.108.174185

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN： 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  9 in total

1.  Very low density lipoprotein. Removal of Apolipoproteins C-II and C-III-1 during lipolysis in vitro.

Authors:  S Eisenberg; J R Patsch; J T Sparrow; A M Gotto; T Olivecrona
Journal:  J Biol Chem       Date:  1979-12-25       Impact factor: 5.157

2.  Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects.

Authors:  M Berman; M Hall; R I Levy; S Eisenberg; D W Bilheimer; R D Phair; R H Goebel
Journal:  J Lipid Res       Date:  1978-01       Impact factor: 5.922

3.  Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins.

Authors:  P R Bukberg; N A Le; H N Ginsberg; J C Gibson; A Rubinstein; W V Brown
Journal:  J Lipid Res       Date:  1985-09       Impact factor: 5.922

4.  Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects.

Authors:  M W Huff; N H Fidge; P J Nestel; T Billington; B Watson
Journal:  J Lipid Res       Date:  1981-11       Impact factor: 5.922

5.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Authors:  Kazunori Nagashima; Carlos Lopez; Daniel Donovan; Colleen Ngai; Nelson Fontanez; André Bensadoun; Jamila Fruchart-Najib; Steve Holleran; Jeffrey S Cohn; Rajasekhar Ramakrishnan; Henry N Ginsberg
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

6.  Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia.

Authors:  Jeffrey S Cohn; Michel Tremblay; Rami Batal; Hélène Jacques; Claudia Rodriguez; George Steiner; Orval Mamer; Jean Davignon
Journal:  Atherosclerosis       Date:  2004-11       Impact factor: 5.162

7.  Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-19       Impact factor: 8.311

8.  Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.

Authors:  Dick C Chan; Minh N Nguyen; Gerald F Watts; P Hugh R Barrett
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

9.  Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans.

Authors:  Mirjana Pavlic; René Valéro; Hélène Duez; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-12       Impact factor: 8.311
  9 in total
  5 in total

1.  Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?

Authors:  Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2011-03-24       Impact factor: 5.922

2.  Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism.

Authors:  Gissette Reyes-Soffer; Carol Sztalryd; Richard B Horenstein; Stephen Holleran; Anastasiya Matveyenko; Tiffany Thomas; Renu Nandakumar; Colleen Ngai; Wahida Karmally; Henry N Ginsberg; Rajasekhar Ramakrishnan; Toni I Pollin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

3.  A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.

Authors:  Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader
Journal:  Nat Med       Date:  2017-08-21       Impact factor: 53.440

Review 4.  Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors:  Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

5.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.